Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | THPO | P40225 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280316 | 0.96 | MAPK1 (0.48) | MAPK1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1319549 | 0.95 | MAPK1 (0.56) | MAPK1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4378225 | 0.92 | HRH4 (0.55) | MAPK1CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL9122689 | 0.82 | CYP19A1 (0.56) | MAPK1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9728037 | 0.81 | CYP19A1 (0.55) | MEN1LMNAKMT2AALDH1A1MAPT | |
| SCHEMBL9119601 | 0.77 | CYP19A1 (0.54) | MAPK1CYP3A4CYP2D6RAB9ATSHR | |
| SCHEMBL9728051 | 0.77 | CYP19A1 (0.51) | MEN1KMT2A | |
| SCHEMBL7961327 | 0.77 | RAB9A (0.43) | RAB9AMEN1LMNAKMT2AKCNH2 | |
| SCHEMBL9771022 | 0.76 | SIGMAR1 (0.43) | MAPK1CYP1A2CYP2D6CYP2C9NFKB1 | |
| SCHEMBL4382483 | 0.76 | CYP19A1 (0.40) | MEN1KMT2ASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248765-B1 | ANTIINFLAMMATORY AGENTS; HYPOTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (FR) | 2001-06-19 | — | — | US | claimed |
| US-20090264470-A1 | CB1 Antagonists and Inverse Agonists | AMPLA PHARMACEUTICALS INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264470-A1 | CB1 Antagonists and Inverse Agonists | AMPLA PHARMACEUTICALS INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090036426-A1 | CB1 antagonists and inverse agonists | AMPLA PHARMACEUTICALS INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036426-A1 | CB1 antagonists and inverse agonists | AMPLA PHARMACEUTICALS INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009017755-A2 | CB1 ANTAGONISTS AND INVERSE AGONISTS | AMPLA PHARMACEUTICALS INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080027087-A1 | CB1 antagonists and inverse agonists | AMPLA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027087-A1 | CB1 antagonists and inverse agonists | AMPLA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2007102999-A2 | CB1 ANTAGONISTS AND INVERSE AGONISTS | AMPLA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-6248765-B1 | ANTIINFLAMMATORY AGENTS; HYPOTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (FR) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264470-A1 | CB1 Antagonists and Inverse Agonists | CNR2, CNR1, GPR119 | MAPK1 2278/4885CYP1A2 1745/4885CYP3A4 3086/4885 |
| US-20080027087-A1 | CB1 antagonists and inverse agonists | CNR2, CNR1, GPR119 | MAPK1 2278/4885CYP1A2 1745/4885CYP3A4 3086/4885 |
| US-20090036426-A1 | CB1 antagonists and inverse agonists | CNR2, GPR119, CNR1 | MAPK1 2833/4885CYP1A2 1129/4885CYP3A4 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.